Acetaminophen; caffeine; dihydrocodeine bitartrate - Generic Drug Details

What are the generic drug sources for acetaminophen; caffeine; dihydrocodeine bitartrate and what is the scope of patent protection?

Acetaminophen; caffeine; dihydrocodeine bitartrate is the generic ingredient in five branded drugs marketed by Mikart, Wraser Pharms Llc, Pharm Res Assoc, Leitner Pharms, Key Therap, Pharmobedient, Boca Pharma Llc, and West-ward Pharm Corp, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for acetaminophen; caffeine; dihydrocodeine bitartrate

US Patents:	0
Tradenames:	5
Applicants:	8
NDAs:	9
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	22
DailyMed Link:	acetaminophen; caffeine; dihydrocodeine bitartrate at DailyMed

Pharmacology for acetaminophen; caffeine; dihydrocodeine bitartrate

Drug Class	Central Nervous System Stimulant Methylxanthine Opioid Agonist
Mechanism of Action	Full Opioid Agonists
Physiological Effect	Central Nervous System Stimulation

Anatomical Therapeutic Chemical (ATC) Classes for acetaminophen; caffeine; dihydrocodeine bitartrate

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

N06BC	Xanthine derivatives
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

US Patents and Regulatory Information for acetaminophen; caffeine; dihydrocodeine bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	TREZIX	acetaminophen; caffeine; dihydrocodeine bitartrate	CAPSULE;ORAL	204785-001	Nov 26, 2014		DISCN	No	No
Mikart	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE	acetaminophen; caffeine; dihydrocodeine bitartrate	CAPSULE;ORAL	040109-001	Aug 26, 1997		DISCN	No	No
Mikart	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE	acetaminophen; caffeine; dihydrocodeine bitartrate	TABLET;ORAL	040316-001	Apr 28, 1999		DISCN	No	No
Pharm Res Assoc	DHC PLUS	acetaminophen; caffeine; dihydrocodeine bitartrate	CAPSULE;ORAL	088584-001	Mar 4, 1986		DISCN	No	No
West-ward Pharm Corp	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE	acetaminophen; caffeine; dihydrocodeine bitartrate	TABLET;ORAL	040637-001	Sep 22, 2006		DISCN	No	No

Acetaminophen; caffeine; dihydrocodeine bitartrate Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Acetaminophen; Caffeine; Dihydrocodeine Bitartrate?

The combination drug—acetaminophen, caffeine, and dihydrocodeine bitartrate—targets analgesic and central nervous system (CNS) applications. Its market hinges on several factors: regulatory status, demand for pain management solutions, and competitive landscape.

Regulatory Environment and Approval Status

• FDA Classification: The US Food and Drug Administration classifies acetaminophen and caffeine as over-the-counter (OTC) ingredients, while dihydrocodeine is a controlled substance (Schedule III).
• Global Variations: Approval status varies by country; controlled substances face stricter regulations outside the US, impacting market access and volume.
• Legal Restrictions: The combination's status as a controlled substance limits prescription volumes, especially in jurisdictions with tight opioid controls.

Market Drivers

• Pain Management Needs: The rise in acute and chronic pain cases drives demand, especially among populations with opioid tolerance or seeking non-typical analgesics.
• Combination Therapy: The perceived benefit of combining NSAIDs (acetaminophen), CNS stimulants (caffeine), and opioids (dihydrocodeine) expands therapeutic options.
• Patient Preference: Consumers increasingly prefer combination drugs for convenience and potentially reduced side effects compared to multiple pills.

Market Challenges

• Regulatory Risks: Stricter controls on opioids and abuse-deterrent formulations threaten supply and sales.
• Public Perception & Safety: Safety concerns surrounding acetaminophen (liver toxicity) and opioids impair market growth.
• Competition: Generic alternatives and other opioid-nonopioid combinations vie for market share.

Key Market Participants

• Manufacturers: GlaxoSmithKline, Johnson & Johnson, and generic producers.
• Distribution: Pharmacy chains and hospitals predominantly handle sales; online distribution faces regulatory hurdles.

Market Trends and Projections

• Historical Growth: The global analgesic market was valued at approximately $12.2 billion in 2021, with a compounded annual growth rate (CAGR) of 4.2% projected through 2028 ([1]).
• Specific Demand Trends: Non-opioid analgesics are gaining appeal due to opioid epidemic concerns, but combination opioids sustain niche demand.
• Emerging Markets: Increased access and healthcare infrastructure growth in Asia and Latin America could expand the market, assuming regulatory adaptations.

---

How Does the Financial Trajectory Look for This Drug?

Revenue Overview

• Burned predominantly by prescription permissions and regulatory constraints, revenues are heavily influenced by regional policies.
• Estimated sales for such combination drugs are modest compared to primary analgesics; in 2021, the global pain medication market generated $13 billion, with limited contribution from opioid combinations ([1]).

Pricing and Revenue Models

• Pricing: Ranges widely based on region, formulation, and manufacturer. In the US, a typical package of prescription acetaminophen/dihydrocodeine might retail at $15–$30 per prescription.
• Market Share: The niche status leads to low-to-moderate market penetration, generally less than 5% of total analgesic sales.

R&D and Regulatory Costs

• High costs associated with obtaining approvals and maintaining compliance, especially for controlled substances.
• Patent protection is limited; generics dominate the market, pressuring prices.

Profitability Outlook

• Margins are constrained by regulatory costs, generic competition, and social pressure.
• Investment focuses on reformulations, abuse-deterrent formulations, or alternative combinations to sustain profitability.

Future Financial Trends

• Maximize potential through geographic expansion, especially where regulation is evolving.
• Innovation into abuse-resistant formulations could open new revenue streams.
• Market constraints suggest slow top-line growth, with an emphasis on cost control.

---

Key Takeaways

• The drug's market hinges on regulatory environments, with controlled substance status posing barriers.
• Demand is driven by pain management needs and combination therapy benefits, but is limited by safety and abuse concerns.
• The competitive landscape is saturated with generics; innovation in abuse resistance and formulations is vital.
• Revenue prospects are modest, constrained by pricing pressures, regulatory hurdles, and societal shifts against opioids.

---

FAQs

1. What are regulatory hurdles for this combination drug?
Controlled substance scheduling and approval processes, especially for dihydrocodeine, lead to strict prescribing and distribution rules that hinder market expansion.

2. How does safety concern affect market growth?
Safety issues related to acetaminophen (liver toxicity) and opioid misuse contribute to regulatory restrictions and reduce demand among certain patient populations.

3. What is the typical price range for this drug?
Around $15–$30 per prescription in the US, with prices varying significantly across regions and formulations.

4. Which markets are likely to see growth?
Emerging markets with evolving regulations and increasing demand for pain management solutions may present growth opportunities if regulatory barriers are relaxed.

5. How does competition influence revenue?
Market is dominated by generics, limiting pricing power and profit margins, with brand-name versions accounting for a small share.

---

References

[1] MarketWatch. "Pain Management Drugs Market Size, Trends & Forecast," 2022.